{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:23:55Z","timestamp":1792196635555,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"This study was sponsored by Novo Nordisk Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03340-2","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:12:39Z","timestamp":1756368759000},"page":"5468-5480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE)"],"prefix":"10.1007","volume":"42","author":[{"given":"Carmen D.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Divino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Toliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Buss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"Suppl","key":"3340_CR1","first-page":"S176","volume":"22","author":"CM Apovian","year":"2016","unstructured":"Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016;22(Suppl):S176\u201385.","journal-title":"Am J Manag Care"},{"key":"3340_CR2","doi-asserted-by":"crossref","unstructured":"Akinbami LJ, Chen TC, Davy O, et al. National Health and Nutrition Examination Survey, 2017-March 2020 prepandemic file: sample design, estimation, and analytic guidelines. Vital Health Stat 1. 2022;190:1\u201336.","DOI":"10.15620\/cdc:115434"},{"key":"3340_CR3","first-page":"354","volume":"27","author":"J Cawley","year":"2021","unstructured":"Cawley J, Biener A, Meyerhoefer C, et al. Direct medical costs of obesity in the United States and the most populous states. J Manag Care Spec Pharm. 2021;27:354\u201366.","journal-title":"J Manag Care Spec Pharm"},{"key":"3340_CR4","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1161\/CIRCRESAHA.116.308999","volume":"118","author":"PE Scherer","year":"2016","unstructured":"Scherer PE, Hill JA. Obesity, diabetes, and cardiovascular diseases: a compendium. Circ Res. 2016;118:1703\u20135.","journal-title":"Circ Res"},{"key":"3340_CR5","unstructured":"Mayo Clinic. Obesity\u2013symptoms and causes. https:\/\/www.mayoclinic.org\/diseases-conditions\/obesity\/symptoms-causes\/syc-20375742#:~:text=People%20with%20obesity%20are%20more%20likely%20to%20develop,liver%20disease.%20...%208%20Severe%20COVID-19%20symptoms.%20. Accessed April 30, 2025."},{"key":"3340_CR6","volume":"16","author":"KE Achara","year":"2024","unstructured":"Achara KE, Iyayi IR, Erinne OC, et al. Trends and patterns in obesity-related deaths in the US (2010\u20132020): a comprehensive analysis using Centers for Disease Control and Prevention wide-ranging online data for epidemiologic research (CDC WONDER) data. Cureus. 2024;16: e68376.","journal-title":"Cureus"},{"key":"3340_CR7","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: a review. JAMA. 2023;330:2000\u201315.","journal-title":"JAMA"},{"issue":"Suppl 2","key":"3340_CR8","first-page":"S102","volume":"129","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014;129(Suppl 2):S102\u201338.","journal-title":"Circulation"},{"issue":"Suppl 3","key":"3340_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","volume":"22","author":"WT Garvey","year":"2016","unstructured":"Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1\u2013203.","journal-title":"Endocr Pract"},{"key":"3340_CR10","unstructured":"Inserro A. FDA clears semaglutide for weight loss when used with diet, exercise. June 4, 2021. https:\/\/www.ajmc.com\/view\/fda-clears-semaglutide-for-weight-loss-when-used-with-diet-exercise. Accessed June 10, 2025."},{"key":"3340_CR11","unstructured":"Eli Lilly and Company. FDA approves Lilly's Mounjaro\u2122 (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and. Accessed April 30, 2025."},{"key":"3340_CR12","unstructured":"US Food & Drug Administration. FDA approves new medication for chronic weight management. November 8, 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-chronic-weight-management. Accessed April 30, 2025."},{"issue":"3","key":"3340_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101636","volume":"51","author":"ER Hankosky","year":"2025","unstructured":"Hankosky ER, Desai K, Chinthammit C, et al. Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States. Diabetes Metab. 2025;51(3): 101636.","journal-title":"Diabetes Metab"},{"key":"3340_CR14","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/dom.16290","volume":"27","author":"ER Hankosky","year":"2025","unstructured":"Hankosky ER, Chinthammit C, Meeks A, et al. Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: results from the Optum Market Clarity database. Diabetes Obes Metab. 2025;27:2810\u201321.","journal-title":"Diabetes Obes Metab"},{"key":"3340_CR15","unstructured":"OZEMPIC\u00ae (semaglutide) injection, for subcutaneous use [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2025."},{"key":"3340_CR16","unstructured":"WEGOVY\u00ae (semaglutide) injection, for subcutaneous use [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2024."},{"key":"3340_CR17","unstructured":"MOUNJARO\u00ae (tirzepatide) injection, solution [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024."},{"key":"3340_CR18","unstructured":"ZEPBOUND\u00ae (tirzepatide) injection, solution [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024."},{"key":"3340_CR19","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1111\/dom.16330","volume":"27","author":"T Hunter Gibble","year":"2025","unstructured":"Hunter Gibble T, Chinthammit C, Ward JM, et al. Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: results from the Veradigm\u00ae database. Diabetes Obes Metab. 2025;27:3185\u201394.","journal-title":"Diabetes Obes Metab"},{"key":"3340_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","volume":"6","author":"DH Ryan","year":"2017","unstructured":"Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6:187\u201394.","journal-title":"Curr Obes Rep"},{"key":"3340_CR21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"3340_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/00325481.2025.2482274","volume":"137","author":"A Ruseva","year":"2025","unstructured":"Ruseva A, Dabbous F, Ding N, et al. Semaglutide 2.4 mg long-term clinical outcomes in patients with obesity or overweight: a real-world retrospective cohort study in the United States (SCOPE 12 months). Postgrad Med. 2025;137:251\u201360.","journal-title":"Postgrad Med"},{"key":"3340_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"3340_CR24","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1111\/dom.16343","volume":"27","author":"H Trinh","year":"2025","unstructured":"Trinh H, Donovan A, McAdam-Marx C. Real-world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting. Diabetes Obes Metab. 2025;27:3523\u20135.","journal-title":"Diabetes Obes Metab"},{"key":"3340_CR25","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","volume":"184","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024;184:1056\u201364.","journal-title":"JAMA Intern Med"},{"key":"3340_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102777","volume":"75","author":"M Anson","year":"2024","unstructured":"Anson M, Henney AE, Broadwell N, et al. Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study. EClinicalMedicine. 2024;75: 102777.","journal-title":"EClinicalMedicine"},{"key":"3340_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069719","volume":"377","author":"CD Madigan","year":"2022","unstructured":"Madigan CD, Graham HE, Sturgiss E, et al. Effectiveness of weight management interventions for adults delivered in primary care: systematic review and meta-analysis of randomised controlled trials. BMJ. 2022;377: e069719.","journal-title":"BMJ"},{"key":"3340_CR28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.gtc.2023.02.003","volume":"52","author":"TB Washington","year":"2023","unstructured":"Washington TB, Johnson VR, Kendrick K, et al. Disparities in access and quality of obesity care. Gastroenterol Clin North Am. 2023;52:429\u201341.","journal-title":"Gastroenterol Clin North Am"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03340-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03340-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03340-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:32Z","timestamp":1762030952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03340-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3340"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03340-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carmen D. Ng, Victoria Divino, Julia Wang, Joshua C. Toliver, and Marcio Buss are employees and shareholders of Novo Nordisk Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with relevant guidelines and regulations, including the principals of the Declaration of Helsinki of 1964 and its later amendments. This study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data.\u00a0The Department of Health and Human Services does not consider analysis of de-identified secondary data to meet the definition for human subject research. Therefore, this study was exempt from federal regulations covering human subject research and did not require institutional review board review. This is as per exemption (d)4 from 45 CFR 46.104. Novo Nordisk Inc. has a data access license to the Komodo Health database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}